17 Aug 10 QRxPharma receives Frost & Sullivan’s 2010 New Product Innovation of the Year Award for MoxDuo IR opiod
Based on its recent analysis of the opioid pain management market, Frost & Sullivan recognizes QRxPharma Limited with the 2010 North American Frost & Sullivan Award for New Product Innovation of the Year for MoxDuo® immediate-release (IR) (Q8003IR) – the first patented dual opioid for the management of pain that also addresses some major challenges experienced by currently marketed opioids.
Excerpt from:
QRxPharma receives Frost & Sullivan’s 2010 New Product Innovation of the Year Award for MoxDuo IR opiod
Tags: north, pharma-limited, sullivan-award
09 Aug 10 Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine
QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma’s formulation of …
See the original post:
Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine
Tags: announced-today, efficacy, morphine-plus, pharma-limited, treatment
09 Aug 10 QRxPharma Announces Positive Phase 2 Proof-of-Concept Data for MoxDuo(R)IV Pain Therapy
Combination of Morphine plus Oxycodone IV Demonstrates Improved Analgesia and Tolerability Compared to IV Morphine SYDNEY and BEDMINSTER, N.J. , Aug 9 /PRNewswire/ — QRxPharma Limited (ASX: QRX.ax – News ) announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV …
See original here:
QRxPharma Announces Positive Phase 2 Proof-of-Concept Data for MoxDuo(R)IV Pain Therapy
Tags: announced-today, demonstrates, efficacy, pharma-limited
23 Feb 10 QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV (PR Newswire via Yahoo! Finance)
QRxPharma Limited , and China Aoxing Pharmaceutical Company announced today a strategic alliance to collaborate in the development of MoxDuo®IV, an intravenous formulation of QRxPharma’s patented morphine and oxycodone Dual-Opioid⢠technology for the acute treatment of moderate to severe pain.  Under the terms of the agreement, China Aoxing will fund the development of MoxDuo®IV for the …
See the original post here:
QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV (PR Newswire via Yahoo! Finance)
Tags: development, officer-stopped, pharma-limited, police-said-, the-development
